92% ORR in pancreatic cancer sets up a Phase 3 bet; whether randomized data replicates a single-arm signal decides everything

Updated 35d ago

Tango Therapeutics is a clinical-stage company developing a targeted cancer drug combination for pancreatic cancer that is not yet approved.

A 92% objective response rate and 90% six-month progression-free survival for vopimetostat plus daraxonrasib in MTAP-deleted pancreatic cancer, a disease with historically dismal outcomes, is the most striking Phase 1/2 result in this space. The thesis resolves on whether a randomized Phase 3 trial, design pending regulatory feedback, confirms that signal rather than exposing single-arm inflation against a strong control arm. IDEAYA Biosciences pursues the same MTAP-deleted target across overlapping indications, and the single-arm nature of the current data leaves approvability genuinely unproven.

Status

Intact

Conviction

Current Thesis Drivers

Vopimetostat + daraxonrasib: 92% ORR, 90% 6-month PFS in MTAP-deleted PDAC
$1.0B cash, runway through commercialization preparation
TNG462 monotherapy: 27% ORR, 179 patients, 2L PDAC mPFS 7.2 months
Approvability unresolved — Phase 3 design awaiting regulatory authority feedback

What could change the thesis?

Phase 3 design feedback: regulators accept it, accelerating path; reject it, delaying program
TNG456 Phase 1/2 data: efficacy signal opens GBM optionality; null result narrows pipeline
IDEAYA MTAP program readout: validates or commoditizes the MTAP-deleted mechanism

Generated from public SEC filings and disclosures. For informational purposes only — not investment advice. Always conduct your own research before making investment decisions.

Thesis log

Tracked in real time as it happened — not reconstructed after the fact

Key value driver

The most decisive event ahead

Bull and bear case

Both sides of the thesis, argued

Pipeline

5 programs · 7 catalysts

Stress Test